Contents

Search

lemborexant (Dayvigo)

Indications: - insomnia Contraindications: - narcolepsy [2] Dosage: - 5-10 mg Tabs: 5 mg, 10 mg Pharmacokinetics: - elimination 1/2life 17-19 hours [2] Adverse effects: - next-day somnolence - impaired driving - cataplexy-like symptoms [2] Mechanism of action: - orexin receptor antagonist

General

sleeping pill receptor antagonist

Database Correlations

PUBCHEM cid=56944144

References

  1. Remaly J FDA Approves Lemborexant (Dayvigo) for Insomnia. Medscape - Dec 23, 2019. https://www.medscape.com/viewarticle/923054
  2. Talebraza S et al Geriatrics Evaluation & Management Tools American Geriatrics Society. 2021 https://geriatricscareonline.org/ProductAbstract/geriatrics-evaluation-management-tools/B007/